XTalks

DECEMBER 17, 2021

Xtalks is taking a look at some of the major stories and innovations of the year in the life sciences, many of which were driven by new, emerging and improved technologies. The year 2021 was all about continuing innovations in the life sciences. Life Science Innovations: Malaria and Influenza Vaccines.

Life Science 98

Life Science Vaccine Vaccination Trials 98

XTalks

DECEMBER 10, 2024

Rilzabrutinib works by targeting BTK, a protein involved in immune cell communication. By inhibiting this protein, the drug disrupts pathways that contribute to platelet destruction and insufficient production. Recent advancements in ITP treatments include CM313, an anti-CD38 monoclonal antibody that achieved a 95.5

Trials 104

Trials Protein Clinical Development Drugs 104

XTalks

MAY 7, 2021

As Novavax awaits emergency use authorization (EUA) from the US Food and Drug Administration (FDA) for its protein-based COVID-19 vaccine NVX-CoV2373, the company shared new data this week on the vaccine’s efficacy against the South African B.1.351 1.351 variant.

Protein 97

Protein Vaccine Vaccination Trials 97

XTalks

MARCH 31, 2023

By growing high quality crystal structures of protein-based therapeutics under microgravity, researchers can gain better insights into their complex structures and stability. The proteins will be analyzed back on Earth using techniques such as X-ray diffraction and compared with crystals from the same biologics grown on Earth.

Protein 97

Protein Research Development Manufacturing 97

Pharmaceutical Technology

JUNE 4, 2023

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

Gene 262

Gene Gene Therapy Genetics DNA 262

XTalks

JANUARY 29, 2021

Data from Eli Lilly and Company’s (NYSE: LLY) Phase III clinical trial evaluating its monoclonal antibody drugs bamlanivimab (LY-CoV555) and etesevimab (LY-CoV016) show that combining the two significantly reduced the risk of COVID-19 hospitalizations and death by 70 percent. percent) compared with 36 events (7.0

Antibody 96

Antibody Clinical Trials Clinical Trials Trials 96

XTalks

MARCH 15, 2021

Eli Lilly (NASDAQ: LLY ) shared the latest results from a late-stage study which show its combination antibody COVID-19 treatment can reduce hospitalizations and deaths by an impressive 87 percent, compared with placebo. The study is part of Lilly’s ongoing Phase III BLAZE-1 trial evaluating the antibody duo.

Antibody 92

Antibody Trials Protein Regulation 92

XTalks

FEBRUARY 29, 2024

Dual-function fusion proteins represent a cutting-edge approach in biopharmaceutical research, offering a promising avenue for the development of novel therapeutics in the treatment of complex diseases such as cancer and autoimmune disorders. At the helm of this venture is Dr. Taylor H. How is your lead program differentiated?

Protein 94

Protein Development Clinical Trials Clinical Trials 94

XTalks

JANUARY 6, 2021

Researchers at the National Institutes of Health (NIH) in the US have isolated small antibodies called “nanobodies” from a llama named Cormac that can block the SARS-CoV-2 coronavirus. Nanobodies are about a quarter of the size, and approximately one tenth of the weight, of a typical human antibody.

Antibody 105

Antibody Protein Bacteria In-Vitro 105

XTalks

JUNE 18, 2021

This is why Regeneron’s announcement of positive clinical trial results that show its antibody cocktail treatment can cut deaths among hospitalized patients is welcome news. It is the first trial to demonstrate that any antibody treatment could improve survival in patients hospitalized with COVID-19. Regeneron Pharmaceuticals Inc.’s

Antibody 75

Antibody Immune Response Trials Clinical Trials 75

Pharmaceutical Technology

APRIL 18, 2023

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

Protein 147

Protein Vaccination Vaccine Production 147

XTalks

JANUARY 29, 2025

Related: Eli Lillys Kisunla (donanemab) Gets Full FDA Approval After Initial Rejection, Gears Up to Take on Leqembi Leqembi was first approved in 2023 as a monoclonal antibody targeting amyloid-beta protofibrils and plaques proteins that cause brain cell damage and cognitive decline in Alzheimers disease.

FDA Approval 66

FDA Approval Antibody Sales Protein 66

XTalks

OCTOBER 12, 2021

14-3-3 zeta) protein, which the UToledo researchers had been studying for its role in immune-related pathologies, such as aortic aneurysms and in signaling pathways involving the pro-inflammatory cytokine interleukin-17. However, they found the opposite to be true, where the protein was actually protective against development of the disease.

Vaccine 105

Vaccine Vaccination Research Immune Response 105

pharmaphorum

JULY 18, 2022

. “It is programmed and coded for the production of the full-length spike protein of the coronavirus. It then elicits an immune response against that spike protein. You have a response with immunoglobulins type G (antibodies) and robust cellular response with both CD4 and CD8 T-cells being activated,” Morgon states.

Vaccine 138

Vaccine Vaccination Development Immune Response 138

XTalks

AUGUST 8, 2022

Medicxi is a prominent international life sciences investment firm that invested in over 60 portfolio companies such as Versanis Bio, Rivus Pharmaceuticals, Capella Bioscience and more. One of Medicxi’s portfolio companies called MiroBio is set to be acquired by Gilead Sciences for approximately $405 million in cash.

Immune Response 98

Immune Response Antibody Life Science Engineer 98

The Pharma Data

SEPTEMBER 4, 2020

The technique has been used to generate a high-affinity antibody against Arginase 2, an enzyme implicated in major human diseases. Therefore, the enzyme is a target for inhibitory therapeutic antibodies that could help restore immune function against cancer cells, the researchers note.

Antibody 52

Antibody Research Life Science Production 52

XTalks

MAY 9, 2024

Genmab, a trailblazer in the field of antibody therapeutics, celebrates this milestone by reflecting on its impressive journey from a small-scale startup to a global leader in cancer treatment and beyond. Since then, innovative science has been at Genmab’s core, as we harness the power of human antibodies to improve the lives of patients.

Antibody 52

Antibody Clinical Trials Clinical Trials Medicine 52

XTalks

APRIL 1, 2025

In hemophilia patients, inhibitors are antibodies that interfere with the effectiveness of clotting factor replacement therapies. Through RNA silencing, it targets the expression of antithrombin, a protein that inhibits blood clotting. The ATLAS-INH trial enrolled 77 patients with inhibitory antibodies to FVIII or FIX.

FDA Approval 52

FDA Approval RNA Clinical Trials Clinical Trials 52

XTalks

JUNE 8, 2022

Amgen’s Riabni, a CD20-directed cytolytic antibody and biosimilar to Rituxan, got approval from the FDA on Monday for adults with moderate to severe rheumatoid arthritis. B-cell targeted therapy with the monoclonal antibody Rituxan (rituximab) is used to treat RA. million Americans. Evidence for the Efficacy of Riabni.

FDA Approval 96

FDA Approval Antibody Clinical Trials Clinical Trials 96

XTalks

JULY 25, 2022

Epidermal growth factor receptor 2 (HER2)-positive breast cancer is one such type in which there is an overexpression of the HER2 protein. Later lines of treatment can include monoclonal antibodies, tyrosine kinase inhibitors and antibody-drug conjugates (ADCs). Vic-]Trastuzumab Duocarmazine Mechanism of Action.

Antibody 59

Antibody Drugs Clinical Trials Clinical Trials 59

XTalks

FEBRUARY 26, 2024

Xolair is a monoclonal antibody that binds to IgE, a type of antibody in the body that triggers allergic reactions, to block it from binding to its receptors. Xolair is the first medication approved by the FDA to reduce allergic reactions to more than one type of food after accidental exposure.

Allergies 100

Allergies FDA Approval Drugs Protein 100

XTalks

JANUARY 6, 2025

However, some patients develop inhibitors antibodies that neutralize the efficacy of replacement therapies. These inhibitors make managing bleeding episodes more challenging, increasing the risk of severe complications such as joint damage, chronic pain and life-threatening hemorrhages. Hympavzi is administered once weekly.

FDA Approval 105

FDA Approval Antibody Drugs Clinical Trials 105

pharmaphorum

JULY 20, 2021

The vaccine – now dubbed Vidprevtyn – is based on a recombinant protein antigen developed by Sanofi’s vaccines unit Sanofi Pasteur, and also includes an immune-boosting adjuvant developed by GSK that aims to boost its efficacy. 1.351) variant first identified in South Africa.

Vaccine 98

Vaccine Vaccination Protein Immune Response 98

Pharmaceutical Technology

MAY 8, 2023

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

Antibody 147

Antibody Vaccination Vaccine Dermatology 147

Pharmaceutical Technology

MARCH 1, 2023

The drug candidate targets DNA-dependent protein kinase (DNA-PK). Merck KG, is a science and technology company. Merck also provides a wide range of products including lab water systems, gene editing tools, cell lines, antibodies and end-to-end systems. It is a new chemical entity. Merck overview Merck, a subsidiary of E.

Gene Editing 100

Gene Editing DNA Cosmetics Life Science 100

Pharmaceutical Technology

MARCH 1, 2023

The drug candidate targets DNA-dependent protein kinase (DNA-PK). Merck KG, is a science and technology company. Merck also provides a wide range of products including lab water systems, gene editing tools, cell lines, antibodies and end-to-end systems. It is a new chemical entity. Merck overview Merck, a subsidiary of E.

Gene Editing 100

Gene Editing DNA Cosmetics Life Science 100

XTalks

FEBRUARY 16, 2022

The US Food and Drug Administration (FDA) has authorized the use of Eli Lilly’s newest COVID-19 monoclonal antibody treatment bebtelovimab. Last month, the FDA revoked the EUA for Lilly’s monoclonal antibody cocktail of bamlanivimab and etesevimab because it wasn’t effective against Omicron.

Antibody 98

Antibody Trials Drugs Clinical Trials 98

pharmaphorum

MARCH 28, 2022

Israel-based AION Labs and German independent research institute BioMed X announced its third global call for applications to form a new start-up company focused on using AI to design and optimise antibodies for targeted therapies. . The partners want to focus on riskier, more complex structures of proteins to try to decipher them.

Pharma Companies 98

Pharma Companies Antibody Protein Development 98

XTalks

OCTOBER 22, 2024

Vyloy is a first-in-class monoclonal antibody that targets the CLDN18.2 transmembrane tight junction protein, which is commonly found in some gastric and GEJ cancers. gene, and an estimated 60 percent of all gastric cancers harbor the protein. targeting antibody-drug conjugate. On the other hand, Merck & Co.

FDA Approval 105

FDA Approval Drugs Licensing Licensing 105

XTalks

APRIL 7, 2021

As the COVID-19 pandemic shifts with new case surges largely owing to new variants of SARS-CoV-2, the US Food and Drug Administration (FDA) continues to offer up emergency use authorizations (EUA) for tests for the detection of COVID-19 infection, with the latest being antibody and antigen tests from Symbiotic and Quidel, respectively.

Antibody 102

Antibody Immune Response Radiology Marketing 102

XTalks

OCTOBER 23, 2024

Sibeprenlimab, which has a Breakthrough Therapy designation, is a monoclonal antibody that blocks APRIL ( A PR oliferation- I nducing L igand), a critical step in the immune cascade contributing to IgAN. IgAN, also known as Berger’s disease, occurs when IgA antibodies build up in the kidneys, leading to inflammation.

Trials 101

Trials Clinical Trials Clinical Trials Antibody 101

XTalks

DECEMBER 12, 2023

Plasma medicine is a critical and specialized field within healthcare, centering on the use of human plasma for the development and administration of life-saving treatments. Human plasma, the clear, liquid portion of blood, is composed of water, electrolytes, nutrients and crucial proteins such as antibodies, clotting factors and albumin.

Medicine 111

Medicine Recombinant Antibody Protein Antibody 111

XTalks

JUNE 23, 2021

The team also talked about Regeneron’s monoclonal antibody treatment for COVID-19 that has been shown to reduce the risk of deaths by 20 percent among hospitalized COVID-19 patients in recent results from the UK RECOVERY trial. The treatment consists of two monoclonal antibodies that target the spike protein of SARS-CoV-2.

Antibody 40

Antibody Life Science Protein Vaccination 40

XTalks

AUGUST 14, 2023

The Janssen Pharmaceutical Companies of Johnson & Johnson announced that its bispecific antibody Talvey (talquetamab-tgvs) received US Food and Drug Administration (FDA) approval as a fifth-line treatment for adult patients with heavily pretreated multiple myeloma. Results were similar at the higher 0.8 mg/kg dose with an ORR of 73.6

FDA Approval 97

FDA Approval Antibody Immune Response Drugs 97

XTalks

AUGUST 17, 2020

protein-based biologics) and vaccine treatments. Monoclonal antibodies : these are antibodies that are designed to bind to specific targets on cells. protein-based biologics) : are those which bind to specific components (i.e. chimeric receptor antigen [CAR] T cell) immune modulators (i.e. Immune system modulators (i.e.

Protein 98

Protein Engineer Immune Response In-Vivo 98

XTalks

JULY 10, 2023

Rystiggo received FDA approval under the Priority Review designation, specifically for the treatment of gMG in adult patients who have tested positive for anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibodies. The active ingredient in Rystiggo is rozanolixizumab, a humanized IgG4 monoclonal antibody.

FDA Approval 98

FDA Approval Antibody Protein Engineer 98

XTalks

JANUARY 31, 2022

Neutralizing Antibody Data for Omicron Targeting. Moderna also announced publication of neutralizing antibody data against omicron following a booster dose of its original vaccine, mRNA-1273, in the New England Journal of Medicine (NEJM) this month. The study showed that antibody neutralization against omicron decreased by 6.3-fold

Vaccine 98

Vaccine Vaccination Trials Antibody 98